You are here: Home » News-CM » Economy » News
Business Standard

4677 Jan Aushadhi Kendras functional as of end 2018

Health Medical Pharma

Capital Market 

Jan Aushadhi Kendras helped to save Rs 1668 crore to the citizens of country

The Minister of State for Road Transport and Highways, Shipping and Chemicals and Fertilizers, Mansukh L. Mandaviya has informed the Rajya Sabha that as on 31 December 2018, 4677 'Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana' (PMBJP) Kendras are functional in 35 States/UTs of the country.

The unbranded generic medicines worth Rs 417 crores (MRP) have been sold through PMBJP Kendras from inception of the scheme till the end of December 2018. This sale is roughly equivalent to sale of Rs 2085 crores of the branded medicines. Thus, PMBJP has resulted in the saving of approximately Rs 1668 crores to the citizens of country.

PMBJP was launched by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India with an objective of making available quality generic medicines at affordable prices to all. Under this scheme, unbranded generic medicines of good quality are made available through outlets called PMBJP Kendras. In order to ensure quality of medicines sold through PMBJP Kendras, the medicines are procured only from WHO-GMP certified manufacturers, the Minister stated.

The product basket of the scheme covers more than 800 medicines and 154 surgicals & consumables covering all 23 major therapeutic groups such as Anti-infectives, Anti-diabetics, Cardiovasculars, Anti-cancers, Gastro-intestinal medicines, etc. The Maximum Retail Price (MRP) of a medicine sold through PMBJP outlets is fixed in such a way that it is at least 50% below the average MRP of corresponding top three brands of that medicine.

The Minister stated that in some cases, the MRP is fixed at such a low rate that it is 90% below the MRP of corresponding branded medicines. Thus, quality generic medicines are made available to people of the country at a much cheaper rate against the prevalent market rate of branded medicines.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, January 04 2019. 18:37 IST